Immune response after inoculation with PPV23 in HIV-infected adults
10.19428/j.cnki.sjpm.2021.20314
- VernacularTitle:HIV感染者接种23价肺炎链球菌多糖疫苗的免疫效果
- Author:
Xiao-hua QIAN
1
;
Hong-bo SHEN
;
Kun CHEN
;
Hui-chang HUANG
;
Li ZHANG
;
Li-yan SUN
;
Ying ZHANG
Author Information
1. Department of Programme on Immunization, The Center for Disease Control and Prevention in Hongkou District, Shanghai 200082, China
- Publication Type:Research Article
- Keywords:
HIV-infected adult;
PPV23;
OPA antibody;
community-acquired pneumonia
- From:
Shanghai Journal of Preventive Medicine
2021;33(2):136-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the functional antibody and protection effect against pneumonia disease after inoculation with PPV23 in HIV-infected adults. Methods In 2015, 63 HIV-infected adults were randomly selected in Hongkou District of Shanghai, and blood samples were collected before and one month after the inoculation of PPV23.Functional antibodies against 4 serotypes (19F, 19A, 23F, 6B) of Streptococcus pneumoniae were detected by opsonophagocyitosis killing assay (OPA).The incidence of pneumonia after PPV23 inoculation was also determined. Results The GMT of OPA antibodies against 4 serotypes 1 month after inoculation with PPV23 was significantly higher than that before inoculation in HIV-infected subjects.After inoculation, the triple growth rates of OPA antibodies against 4 serotypes in HIV-infected subjects were 50%-91.67%.The protection rate against pneumonia was 100% in 2 years after PPV23 inoculation in HIV-infected subjects when compared with same group before inoculation as well as the control group.The HIV-infected patients who received highly active antiretroviral therapy (HAART) or had CD4 count of≥300/μL showed better response in production of OPA antibodies and obtained protection against community-acquired pneumonia (CAP) after receiving PPV23. Conclusion Routine vaccination of PPV23 is recommended for HIV-infected patients with good basic conditions.
